Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Nov;47(11):3647-50.
doi: 10.1128/AAC.47.11.3647-3650.2003.

Activity of posaconazole in treatment of experimental disseminated zygomycosis

Eric Dannaoui  1 , Jacques F G M Meis, David Loebenberg, Paul E Verweij
Affiliations

Activity of posaconazole in treatment of experimental disseminated zygomycosis

Eric Dannaoui et al. Antimicrob Agents Chemother. 2003 Nov.

Abstract

Three isolates of zygomycetes were used to produce a disseminated infection in nonimmunocompromised mice. Against all zygomycete strains, amphotericin B significantly prolonged survival. Itraconazole was inactive against Rhizopus microsporus and Rhizopus oryzae but was partially active against Absidia corymbifera. Posaconazole had no beneficial effects against R. oryzae but showed partial activity against A. corymbifera. Posaconazole had a clear dose-response effect against R. microsporus.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Cumulative mortality for mice infected with R. microsporus AZN 1185 (A), R. oryzae AZN 6373 (B), and A. corymbifera AZN 4095 (C and D) in treated and control groups. Symbols: ▴, itraconazole at 50 mg/kg BID; ▪, amphotericin B at 1 mg/kg OD; ▾, posaconazole at 5 mg/kg OD; ▿, posaconazole at 25 mg/kg OD; •, posaconazole at 40 mg/kg OD; ◊, posaconazole at 100 mg/kg OD; □, control, 5% glucose intraperitoneally; ▵, control, methylcellulose per os.
See this image and copyright information in PMC

References

    1. Cacciapuoti, A., D. Loebenberg, E. Corcoran, F. Menzel, Jr., E. L. Moss, Jr., C. Norris, M. Michalski, K. Raynor, J. Halpern, C. Mendrick, B. Arnold, B. Antonacci, R. Parmegiani, T. Yarosh-Tomaine, G. H. Miller, and R. S. Hare. 2000. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44:2017-2022. - PMC - PubMed
    1. Dannaoui, E., J. Meletiadis, J. W. Mouton, J. F. Meis, and P. E. Verweij. 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51:45-52. - PubMed
    1. Dannaoui, E., J. W. Mouton, J. F. Meis, and P. E. Verweij. 2002. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob. Agents Chemother. 46:1953-1959. - PMC - PubMed
    1. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202. - PMC - PubMed
    1. Galgiani, J. N., and M. L. Lewis. 1997. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. 41:180-183. - PMC - PubMed

Publication types

LinkOut - more resources